Inherited thrombophilia and the eye

Seminars in Ophthalmology

Volumn 23, Issue 2, 2008, Pages 111-119

  Czerlanis, Cheryl ^a   Jay, Walter M ^a   Nand, Sucha ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Factor V Leiden; Hyperhomocysteinemia; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ANTITHROMBIN III DEFICIENCY; ARTERY THROMBOSIS; BRANCH RETINAL ARTERY OCCLUSION; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; EYE DISEASE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; MULTIVARIATE ANALYSIS; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SYSTEMIC DISEASE; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EYE DISEASES; FACTOR V; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 40349087037     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530801888154     Document Type: Review

References (50)

1. Ben-Ami R, Zeltser D, Leibowitz I, Berliner SA. Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. Blood Coagul Fibrinolysis 2002; 13(1): 57-59.
2. Bertram B, Remky A, Arend O, Wolf S, Reim M. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4(6): 332-335.
3. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997; 98(4): 907-909.
4. Cattaneo, M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32(7): 716-723.
5. Chung I, Lip GY. Virchow's triad revisited: blood constituents. Pathophysiol Haemost Thromb 2003; 33(5-6): 449-454.
6. Ciardella AP, Yannuzzi LA, Freund KB, DiMichele D, Nejat M, De Rosa JT, et al. Factor V Leiden, activated protein C resistance, and retinal vein occlusion. Retina 1998; 18(4): 308-315.
7. Clemetson KJ. A short history of platelet glycoprotein Ib complex. Thromb Haemost 2007; 98(1): 63-68.
8. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314(20): 1298-1304.
9. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74(6): 2082-2088.
10. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003; 138(2): 128-134.
11. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90(3): 1004-1008.
12. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44(2): 106-113.
13. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998; 24(4): 367-379.
14. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87(9): 3531-3544.
15. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 2006; 91(5): 695-698.
16. Demirci FY, Guney DB, Akarcay K, Kir N, Ozbek U, Sirma S, et al. Prevalence of factor V Leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand 1999; 77(6): 631-633.
17. Dhar-Munshi S, Ayliffe WH, Jayne D. Branch retinal arteriolar occlusion associated with familial factor V Leiden polymorphism and positive rheumatoid factor. Arch Ophthalmol 1999; 117(7): 971-973.
18. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007; 131(6): 872-884.
19. Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002; 16(1): 98-106.
20. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993; 37(6): 393-417.
21. Garcia DA, Khamashta MA, Crowther MA. (2007). How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 2007; 110(9): 3122-3127.
22. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenberg N. Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. J Lab Clin Med 2004; 143(3): 184-192.
23. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenberg N. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Clin Appl Thromb Hemost 2005; 11(4): 375-389.
24. Golub BM, Sibony PA, Coller BS. Protein S deficiency associated with central retinal artery occlusion. Arch Ophthalmol 1990; 108(7): 918.
25. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116(5): 577-579.
26. Greiner K, Peetz D, Winkgen A, Prellwitz W, Pfeiffer N, Hafner G. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol 1999; 23(3): 155-160.
27. Greven CM, Weaver RG, Owen J, Slusher MM. Protein S deficiency and bilateral branch retinal artery occlusion. Ophthalmology 1991; 98(1): 33-34.
28. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131(1): 61-77.
29. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93(6): 1021-1026.
30. Kalayci D, Gurgey A, Guven D, Parlak H, Hasiripi H. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 1999; 77(6): 622-624.
31. Lahey JM, Tunc M, Kearney J, Modlinski B, Koo H, Johnson RN, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002; 109(1): 126-131.
32. Larsson J. Central retinal artery occlusion in a patient homozygous for factor V Leiden. Am J Ophthalmol 2000; 129(6): 816-817.
33. Larsson J, Hillarp A, Olafsdottir E, Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77(6): 634-637.
34. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80(3): 200-202.
35. Linna T. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thrombosis Haemostasis 1997; 77(1): 214-216.
36. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2(8038): 581-584.
37. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86(3): 772-776.
38. Marcucci R, Bertini L, Liotta AA, Rogolino A, Antonucci E, Ilari I, et al. Activated protein C resistance is a risk factor for central retinal vein occlusion. Ann Ital Med Int 2000; 15(3): 195-198.
39. Marcucci R, Sodi A, Giambene B, Liotta AA, Poli D, Mannini L, et al. Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coagul Fibrinolysis 2007; 18(4): 321-326.
40. Nagy V, Steiber Z, Takacs L, Vereb G, Berta A, Bereczky Z, et al. Trombophilic screening for nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2006; 244(1): 3-8.
41. Nelson ME, Talbot JF, Preston FE. Recurrent multiple-branch retinal arteriolar occlusions in a patient with protein C deficiency. Graefes Arch Clin Exp Ophthalmol 1989; 227(5): 443-447.
42. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10): 3698-3703.
43. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127(10): 895-903.
44. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 2007; 131(6): 866-871.
45. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19(3): 511-518.
46. Shaw DM. Factor V Leiden: an overview. Clin Lab Sci 2006; 19(4): 218-221.
47. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120(8): 728-733.
48. Tekeli O, Gursel E, Buyurgan H. Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand 1999; 77(6): 628-630.
49. Van Cott EM, Laposata M, Hartnett ME. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis 2004; 15(5): 393-397.
50. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996; 80(3): 203-208.